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On June 24, leading experts in the field of research joined PAN at Georgetown University for a panel discussion on the drug development pipeline. This insightful discussion provided participants with a better understanding of how research is moved through the pipeline and ultimately into the hands of patients in the form of new therapies and drugs. The lively panel discussion generated far more questions than the panelists were able to respond to. As a way to address these questions, PAN created a discussion page where a selection of questions from the Webcast is posted. PAN encouraged researchers and clinicians to take this opportunity to respond to these questions and for others to post new questions arising from this Webcast.
KEY RESEARCH ACCOMPLISHMENTS/REPORTABLE OUTCOMES:
 Live Emerging Therapies Webcast held on June 24, 2011 viewed by 422 individuals throughout the country.  Archived Emerging Therapies Webcast viewed by more than 80 additional individuals to-date available online at http://www.parkinsonsaction.org/parkinsonsdisease/emerging-therapies-webcast.  Discussion page created for researchers and clinicians to answer questions of those who viewed the live Webcast.
